Inventor · disambiguated record
Antonia Lopez-Girona
Also filed as: LOPEZ-GIRONA ANTONIA
40 granted patents·19 pending applications·181 citations·filing 2000–2025
97Inventor score
Files withCELGENE CORP43SIGNAL PHARM LLC7PAGANO MICHELE3SCRIPPS RESEARCH INST2BRISTOL MYERS SQUIBB CO1
Top patents by PatentIndex Score
59 records- 0197US9499514B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2015·Granted Nov 22, 2016·28 cites·29 claims
- 0296US11185543B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2020·Granted Nov 30, 2021·5 cites·20 claims
- 0396US10047151B2Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictorCELGENE CORP·Filed 2016·Granted Aug 14, 2018·19 cites·5 claims
- 0495US10357489B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Granted Jul 23, 2019·20 cites·26 claims
- 0594US10648983B2Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapiesCELGENE CORP·Filed 2017·Granted May 12, 2020·9 cites·27 claims
- 0694US9808451B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2016·Granted Nov 7, 2017·12 cites·19 claims
- 0792US9968596B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2017·Granted May 15, 2018·8 cites·26 claims
- 0892US9493466B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2012·Granted Nov 15, 2016·7 cites·5 claims
- 0990US11666579B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jun 6, 2023·2 cites·21 claims
- 1090US11241423B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2019·Granted Feb 8, 2022·2 cites·6 claims
- 1190US9857359B2Methods for determining drug efficacy using cereblon-associated proteinsCELGENE CORP·Filed 2013·Granted Jan 2, 2018·11 cites·15 claims
- 1290US9365640B2Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictorLOPEZ-GIRONA ANTONIA·Filed 2012·Granted Jun 14, 2016·16 cites·19 claims
- 1389US9505764B2Treatment of cancer with dihydropyrazino-pyrazinesSIGNAL PHARM LLC·Filed 2014·Granted Nov 29, 2016·11 cites·33 claims
- 1488US10668057B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2018·Granted Jun 2, 2020·3 cites·7 claims
- 1588US10245258B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2017·Granted Apr 2, 2019·8 cites·43 claims
- 1688US10092555B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2015·Granted Oct 9, 2018·8 cites·7 claims
- 1786US11726080B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2021·Granted Aug 15, 2023·1 cites·21 claims
- 1885US11460471B2Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapiesCELGENE CORP·Filed 2020·Granted Oct 4, 2022·1 cites·29 claims
- 1984US12510533B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2023·Granted Dec 30, 2025·0 cites·18 claims
- 2083US11419861B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2020·Granted Aug 23, 2022·1 cites·7 claims
- 2183US11390617B2Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jul 19, 2022·1 cites·31 claims
- 2282US11628172B2Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Apr 18, 2023·1 cites·25 claims
- 2382US11358952B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Jun 14, 2022·1 cites·21 claims
- 2482US10969381B2Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrileCELGENE CORP·Filed 2019·Granted Apr 6, 2021·1 cites·16 claims
- 2582US9937170B2Treatment of cancer with TOR kinase inhibitorsSIGNAL PHARM LLC·Filed 2016·Granted Apr 10, 2018·1 cites·5 claims
- 2682US2024207255A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2024·Application pending·0 cites
- 2780US12474342B2Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapiesCELGENE CORP·Filed 2022·Granted Nov 18, 2025·0 cites·25 claims
- 2880US2024217955A1Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 2980US2024400548A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2024·Application pending·0 cites
- 3079US2022387413A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Application pending·0 cites
- 3178US12396995B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2023·Granted Aug 26, 2025·0 cites·34 claims
- 3278US10830762B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2016·Granted Nov 10, 2020·1 cites·8 claims
- 3378US2025352551A1Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2025·Application pending·0 cites
- 3477US12103923B2Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2022·Granted Oct 1, 2024·0 cites·23 claims
- 3577US12029738B2Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2021·Granted Jul 9, 2024·0 cites·23 claims
- 3677US11945804B2Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Granted Apr 2, 2024·0 cites·23 claims
- 3776US12178822B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dionCELGENE CORP·Filed 2023·Granted Dec 31, 2024·0 cites·26 claims
- 3876US2023158009A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2023·Application pending·0 cites
- 3974US2022273650A1Treatment of cancer with tor kinase inhibitorsSIGNAL PHARM LLC·Filed 2021·Application pending·0 cites
- 4073US2024208937A1Compounds and Their Use for Treatment of HemoglobinopathiesBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 4170US11733233B2Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligasesCELGENE CORP·Filed 2020·Granted Aug 22, 2023·0 cites·17 claims
- 4268US11590117B2Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2020·Granted Feb 28, 2023·0 cites·21 claims
- 4368US11583536B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2020·Granted Feb 21, 2023·0 cites·41 claims
- 4468US2023210859A1Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2023·Application pending·0 cites
- 4566US6440732B1Genes and proteins encoded therebySCRIPPS RESEARCH INST·Filed 2000·Granted Aug 27, 2002·3 cites·19 claims
- 4666US2020113896A1Methods for treating cancer using tor kinase inhibitor combination therapySIGNAL PHARM LLC·Filed 2019·Application pending·0 cites
- 4764US8119421B2Methods to identify compounds useful for the treatment of proliferative and differentiative disordersPAGANO MICHELE·Filed 2008·Granted Feb 21, 2012·0 cites·13 claims
- 4864US2018221361A1Antiproliferative compounds and methods of use thereofCELGENE CORP·Filed 2018·Application pending·0 cites
- 4959US7479541B2Human and murine Mus81 proteinsSCRIPPS RESEARCH INST·Filed 2007·Granted Jan 20, 2009·0 cites·6 claims
- 5059US2019175573A1Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2019·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Antonia Lopez-Girona files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →